Healthcare / Drug Manufacturers - Specialty & GenericTaiwan
$56.00
+0.20 (+0.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.1B · quality 83.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.9B
P/E
16.9x
↓EV/EBITDA
9.2x
↓ROE
10.8%
↑Gross Margin
43.5%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.6%
FCF CAGR
+8.1%
FCF margin
12.0%
FCF / Net income
1.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.38B · net income $880.8M · FCF $1.01B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.38B | $8.38B | $8.03B | $7.03B | $7.31B |
| Net Income | $880.8M | $880.8M | $1.17B | $827.3M | $839.0M |
| EBITDA | $1.62B | $1.62B | $1.95B | $1.47B | $1.47B |
| EPS | — | — | 4.39 | 3.11 | 3.15 |
| Gross Margin | 43.5% | 43.5% | 43.8% | 42.4% | 43.0% |
| Operating Margin | 15.8% | 15.8% | 16.1% | 13.2% | 10.4% |
| Net Margin | 10.5% | 10.5% | 14.5% | 11.8% | 11.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.15 | 0.17 | 0.26 |
| Current Ratio | 2.63 | 2.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.01B | $1.01B | $1.13B | $1.09B | $796.5M |
| Returns | |||||
| ROE | 10.8% | 10.8% | 14.7% | 11.3% | 11.7% |
| Valuation | |||||
| P/E | 16.92 | 16.92 | 12.30 | 15.19 | 14.05 |
| EV/EBITDA | 9.22 | 9.22 | 7.07 | 8.41 | 7.92 |
| P/B | 1.83 | 1.83 | 1.81 | 1.71 | 1.65 |
| Growth & Yield | |||||
| Revenue Growth | 4.3% | 4.3% | 14.3% | -3.9% | — |
| EPS Growth | — | — | 41.2% | -1.3% | — |
| Dividend Yield | 5.4% | 5.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.6%
Start / end P/E
n/dx → n/dx
EPS bridge
4.39 → n/d
Residual
-8.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.